Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
11 tulemused
Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
CROSS REFERENCE TO RELATED APPLICATION
This application is a National Stage of International Application No. PCT/KR2011/009914 filed Dec. 21, 2011, claiming priority based on Korean Patent Application No. 10-2010-0132955 filed Dec. 23, 2010, the contents of all of which are incorporated herein by
Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a National Stage of International Application No. PCT/KR2010/007160 filed on Oct. 19, 2010, which claims priority from Korean Patent Application No. 10-2009-0099219, filed on Oct. 19, 2009, the contents of all of which are incorporated
24 kilodalton cytoplasmic protease activating DNA fragmentation in apoptosis
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
The present invention relates to proteases involved in apoptosis signalling pathways, to processes for the purification of the proteases, and more particularly to methods for the use of the proteases to modulate apoptosis in target cells.
BACKGROUND OF THE INVENTION
Necrosis
Blockade of inflammatory proteases with cyclic peptides
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
This invention relates to the use of cyclic peptides for modulating cytokine activity, including signaling and inflammatory pathways, in various diseases. More particularly, cyclic peptides possess hereto unknown biological activities, such as inhibition of sheddases and other
Method and reagent for monitoring apoptosis and distinguishing apoptosis from necrosis
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
1. Technical Field of the Invention
This invention relates generally to cytoenzymology, and more particularly to methods and reagents used in cytoenzymology.
2. Discussion of the Background Art
Apoptosis, or programmed cell death, is a process that involves the activation
Composition for collecting and preserving placental stem cells and methods of using the composition
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
1. INTRODUCTION
The present invention relates to improved methods and compositions for the collection of placental stem cells, e.g., by perfusion or physical and/or enzymatic disruption of a placenta or a part thereof, and methods of collecting the stem cells using the compositions. The compositions
Composition for collecting placental stem cells and methods of using the composition
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
1. INTRODUCTION
The present invention relates to improved methods and compositions for the collection of placental stem cells, e.g., by perfusion or physical and/or enzymatic disruption of a placenta or a part thereof, and methods of collecting the stem cells using the compositions. The compositions
Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
This invention relates to secretion of heterologous bioactive proteins, in particular, granulocyte macrophage colony stimulating factor ("GM-CSF") by an expression system inserted into a host selected from the Streptomyces genera.
BACKGROUND OF THE INVENTION
In producing
Use of tumor factor inhibitors together with antiviral agents and therapeutic compositions thereof against HIV infection
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The present invention relates to de novo compositions of matter for the treatment of AIDS. The present invention further relates to the de novo compositions of matter containing TNF inhibitors and antiviral agents selected from the group of reverse transcriptase inhibitors, protease inhibitors, gene
Combination therapy for conditions leading to bone loss
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
The invention relates generally to polypeptides involved in the regulation of bone metabolism. More particularly, the invention relates to a novel polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily. The polypeptide is used
TNF-.alpha. converting enzyme inhibitory agents and method of using same
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
The invention relates to the field of metalloproteases. Specifically, the invention relates to activation or inhibition of the ADAM family of proteases. More specifically, the invention relates to activation or inhibition of the TNF-.alpha. converting enzyme (TACE).
BACKGROUND
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
